IRF4 silencing inhibits Hodgkin lymphoma cell proliferation, survival and CCL5 secretion

Donatella Aldinucci, Marta Celegato, Cinzia Borghese, Alfonso Colombatti, Antonino Carbone

Research output: Contribution to journalArticlepeer-review


Interferon regulatory factor 4 (IRF4) expression is detected in many lymphoid and myeloid malignancies, and may be a promising therapeutic target. IRF4 is strongly expressed in classical Hodgkin lymphoma (cHL) and its expression is up-regulated by CD40L and down-regulated by both anti-proliferative and pro-apoptotic stimuli. This study analysed the effects of IRF4 silencing in a panel of HL-derived cell lines. We demonstrated that IRF4 down-modulation determined a remarkable decrease of both cell number and clonogenic growth in L-1236, L-428, KM-H2 and HDLM-2 cells, but not in IRF4-negative L-540 cells. IRF4 silencing induced apoptosis, as evaluated by caspase-3 activation and Annexin-V staining and up-regulation of the pro-apoptotic molecule Bax. CD40 engagement by both soluble and membrane bound-CD40L almost totally reduced IRF4 down-modulation and growth inhibition by IRF4 silencing in both L-1236 and L-428 cells. Finally, IRF4 silencing decreased CCL5 secretion in all HL cell lines tested and CCL17 in KM-H2 cells. Taken together, our results demonstrated that IRF4 down-modulation by IRF4 silencing was reversed by CD40 engagement, inhibited HL cells proliferation, induced apoptosis and decreased CCL5 secretion, thus suggesting that IRF4 may be involved in HL pathobiology.

Original languageEnglish
Pages (from-to)182-190
Number of pages9
JournalBritish Journal of Haematology
Issue number2
Publication statusPublished - Jan 2011


  • CD40
  • Chemokines
  • Hodgkin lymphoma
  • IRF4/MUM1
  • Microenvironment

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'IRF4 silencing inhibits Hodgkin lymphoma cell proliferation, survival and CCL5 secretion'. Together they form a unique fingerprint.

Cite this